PUBLISHER: Allied Market Research | PRODUCT CODE: 1139971
PUBLISHER: Allied Market Research | PRODUCT CODE: 1139971
The digestive enzymes market was valued at $699.4 million in 2021, and is projected to reach $1,643.6 million by 2031, registering a CAGR of 8.7% from 2022 to 2031.
Digestive enzymes break down proteins, carbohydrates, and lipids and their supplementation play a role in management of digestive disorders, from lactose intolerance to cystic fibrosis. Several formulations of digestive enzymes are available in the market, being different from each other in terms of enzyme type, source & origin, and dosage. Animals-derived enzymes represent an established standard of care. However, the growing study of plants-based and microbe-derived enzymes offer great advancements of digestive enzyme therapy. Moreover, pancreatic enzyme supplementation is the therapy of choice for management of exocrine pancreatic insufficiency (EPI) in chronic pancreatitis, pancreatic cancer, cystic fibrosis (CF), or diabetes. Required daily dose of enzymes is variable, being related to etiology and severity of clinical features of patients, such as age & body weight and for cystic fibrosis, genotype and intestinal factors affect absorption.
The digestive enzymes market trends like increase in prevalence of digestive problems, increase in unhealthy lifestyle by population, and rise in geriatric population are key factors that fuel growth of the digestive enzyme market. Moreover, surge in number of fitness centers and gymnasiums has also increased demand for dietary supplements, increase in awareness about GI health, and focus on preventive disease management are other factors that contribute toward growth of the market. However, lack of knowledge regarding appropriate dosage amounts and presence of substitutes for digestive enzyme supplements are expected to hinder growth of the market. Conversely, development of customized digestive enzymes offer lucrative opportunities for growth of the market.
The digestive enzymes market is segmented into origin, enzyme type, application, and region. By origin, the market is categorized into animals, microbial, and plants. Further, the animals segment is categorized into prescription medicine, sports nutrition, and infant nutrition. The sports nutrition segment for animals is classified into sports drink and other sport supplements. Further, the microbial segment is categorized into prescription medicine, sports nutrition, and infant nutrition. In addition, the sports nutrition segment for microbial is classified into sports drink and other sport supplements. The plants segment is further categorized into prescription medicine, sports nutrition, and infant nutrition. The sports nutrition for plants is classified into sports drink and other sport supplements. By enzyme type, the market is divided into carbohydrase, protease, lipase, and others. By application, it is divided into prescription medicine, sports nutrition, and infant nutrition. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major companies profiled in the report include Abbott Laboratories, AbbVie Inc., Amway Corporation, Archer Daniels Midland Company, Biotics Research Corporation, Brain Group Co Ltd., Country Life, LLC, Douglas Laboratories, Garden of Life, International Flavors & Fragrances Inc, Johnson & Johnson, Metagenics Inc., Mimi's Rock Corporation, Otsuka Holding Co ltd, Soho Flordis International Health, The Enzymedica Group, Vox Nutrition.
Key Benefits For Stakeholders
Key Market Segments
By Origin
By Enzyme Type
By Applications
By Region